US3547119A
(en)
|
1967-12-08 |
1970-12-15 |
Baxter Laboratories Inc |
Catheter assembly
|
US4311137A
(en)
|
1980-04-30 |
1982-01-19 |
Sherwood Medical Industries Inc. |
Infusion device
|
US4531937A
(en)
|
1983-01-24 |
1985-07-30 |
Pacesetter Systems, Inc. |
Introducer catheter apparatus and method of use
|
EP0206497B1
(fr)
|
1985-05-15 |
1994-07-20 |
The Wellcome Foundation Limited |
Nucléosides thérapeutiques et leur préparation
|
US4755173A
(en)
|
1986-02-25 |
1988-07-05 |
Pacesetter Infusion, Ltd. |
Soft cannula subcutaneous injection set
|
US5149820A
(en)
|
1987-03-11 |
1992-09-22 |
Norsk Hydro A.S. |
Deuterated compounds
|
GB8815265D0
(en)
|
1988-06-27 |
1988-08-03 |
Wellcome Found |
Therapeutic nucleosides
|
US5232928A
(en)
|
1989-07-25 |
1993-08-03 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Tetrahydroisoquinoline amides
|
US5545143A
(en)
|
1993-01-21 |
1996-08-13 |
T. S. I. Medical |
Device for subcutaneous medication delivery
|
US5624949A
(en)
|
1993-12-07 |
1997-04-29 |
Eli Lilly And Company |
Protein kinase C inhibitors
|
US6334997B1
(en)
|
1994-03-25 |
2002-01-01 |
Isotechnika, Inc. |
Method of using deuterated calcium channel blockers
|
US6693072B2
(en)
|
1994-06-02 |
2004-02-17 |
Aventis Pharmaceuticals Inc. |
Elastase inhibitors
|
US5756466A
(en)
|
1994-06-17 |
1998-05-26 |
Vertex Pharmaceuticals, Inc. |
Inhibitors of interleukin-1β converting enzyme
|
US5847135A
(en)
|
1994-06-17 |
1998-12-08 |
Vertex Pharmaceuticals, Incorporated |
Inhibitors of interleukin-1β converting enzyme
|
US5968895A
(en)
|
1996-12-11 |
1999-10-19 |
Praecis Pharmaceuticals, Inc. |
Pharmaceutical formulations for sustained drug delivery
|
US6767991B1
(en)
|
1997-08-11 |
2004-07-27 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis C inhibitor peptides
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
US7157430B2
(en)
|
1998-10-22 |
2007-01-02 |
Idun Pharmaceuticals, Inc. |
(Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases
|
US6376531B1
(en)
|
1998-11-13 |
2002-04-23 |
Rupert Charles Bell |
Method of treatment using deuterium compounds
|
US6608027B1
(en)
|
1999-04-06 |
2003-08-19 |
Boehringer Ingelheim (Canada) Ltd |
Macrocyclic peptides active against the hepatitis C virus
|
UA74546C2
(en)
|
1999-04-06 |
2006-01-16 |
Boehringer Ingelheim Ca Ltd |
Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
|
US7256005B2
(en)
|
1999-08-10 |
2007-08-14 |
The Chancellor, Masters And Scholars Of The University Of Oxford |
Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
|
WO2001074768A2
(fr)
|
2000-04-03 |
2001-10-11 |
Vertex Pharmaceuticals Incorporated |
Inhibiteurs de serine proteases, notamment de la protease ns3 du virus de l'hepatite c
|
ES2317900T3
(es)
|
2000-04-05 |
2009-05-01 |
Schering Corporation |
Inhibidores de serina proteasa ns3 macrociclicos del virus de la hepatitis c que comprenden fragmentos n-ciclicas p2.
|
NZ521456A
(en)
|
2000-04-19 |
2004-07-30 |
Schering Corp |
Macrocyclic NS3-Serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
|
US7012066B2
(en)
|
2000-07-21 |
2006-03-14 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
US7244721B2
(en)
|
2000-07-21 |
2007-07-17 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
ES2263687T3
(es)
|
2000-11-20 |
2006-12-16 |
Bristol-Myers Squibb Company |
Inhibidores tripeptidicos de la hepatitis c.
|
CA2446380A1
(fr)
|
2001-05-08 |
2002-11-14 |
Yale University |
Composes proteomimetiques et procedes correspondants
|
DE10129832A1
(de)
|
2001-06-17 |
2003-07-10 |
Berolina Drug Dev Ab Svedala |
Deuterierte N- und alpha-substituierte Diphenylalkoxyessigsäureaminoalkylester sowie diese Verbindungen enthaltende Arzneimittel
|
NZ530000A
(en)
|
2001-07-11 |
2007-03-30 |
Vertex Pharma |
Peptidomimetic bridged bicyclic serine protease inhibitors
|
DE10162121A1
(de)
|
2001-12-12 |
2003-06-18 |
Berolina Drug Dev Ab Svedala |
Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel
|
US6867185B2
(en)
|
2001-12-20 |
2005-03-15 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
US7119072B2
(en)
|
2002-01-30 |
2006-10-10 |
Boehringer Ingelheim (Canada) Ltd. |
Macrocyclic peptides active against the hepatitis C virus
|
CA2369711A1
(fr)
|
2002-01-30 |
2003-07-30 |
Boehringer Ingelheim (Canada) Ltd. |
Peptides macrocycliques qui agissent contre le virus de l'hepatite c
|
CA2369970A1
(fr)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Tri-peptides inhibiteur de l'hepatite c
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
CA2370400A1
(fr)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Tri-peptides inhibiteur de l'hepatite c
|
US7091184B2
(en)
|
2002-02-01 |
2006-08-15 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
US6828301B2
(en)
|
2002-02-07 |
2004-12-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for hepatitis C viral protease inhibitors
|
US7273885B2
(en)
|
2002-04-11 |
2007-09-25 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
JP4942915B2
(ja)
|
2002-04-26 |
2012-05-30 |
ギリアード サイエンシーズ, インコーポレイテッド |
Hivプロテアーゼ阻害剤化合物のホスホネートアナログの細胞蓄積
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
WO2004032827A2
(fr)
|
2002-05-20 |
2004-04-22 |
Bristol-Myers Squibb Company |
Inhibiteurs du virus de l'hepatite c
|
ATE413411T1
(de)
|
2002-05-20 |
2008-11-15 |
Bristol Myers Squibb Co |
Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
|
DE60334205D1
(en)
|
2002-05-20 |
2010-10-28 |
Bristol Myers Squibb Co |
Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
|
JP3598381B2
(ja)
|
2002-07-02 |
2004-12-08 |
独立行政法人物質・材料研究機構 |
一般式;BNで示され、六方晶系5H型ないしは6H型多形構造を有し、紫外域で発光するsp3結合型窒化ホウ素とその製造方法、及びこれを利用した機能性材料
|
US20040138109A1
(en)
|
2002-09-30 |
2004-07-15 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Potent inhibitor of HCV serine protease
|
PL199412B1
(pl)
|
2002-10-15 |
2008-09-30 |
Boehringer Ingelheim Int |
Nowe kompleksy rutenu jako (pre)katalizatory reakcji metatezy, pochodne 2-alkoksy-5-nitrostyrenu jako związki pośrednie i sposób ich wytwarzania
|
US7601709B2
(en)
|
2003-02-07 |
2009-10-13 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic hepatitis C serine protease inhibitors
|
US20040180815A1
(en)
|
2003-03-07 |
2004-09-16 |
Suanne Nakajima |
Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
|
CA2516016C
(fr)
|
2003-03-05 |
2012-05-29 |
Boehringer Ingelheim International Gmbh |
Composes d'inhibition de l'hepatite c
|
UY28240A1
(es)
|
2003-03-27 |
2004-11-08 |
Boehringer Ingelheim Pharma |
Fases cristalinas de un potente inhibidor de la hcv
|
EP1613353A1
(fr)
|
2003-04-02 |
2006-01-11 |
Boehringer Ingelheim International GmbH |
Compositions pharmaceutiques contenant des inhibiteurs de protease virale de l'hepatite c
|
WO2004092203A2
(fr)
|
2003-04-10 |
2004-10-28 |
Boehringer Ingelheim International, Gmbh |
Procede de preparation de composes macrocycliques
|
EP1613620A1
(fr)
|
2003-04-11 |
2006-01-11 |
Vertex Pharmaceuticals Incorporated |
Inhibiteurs des serine proteases, en particulier de la protease ns3-ns4a du vhc
|
ES2386161T3
(es)
|
2003-04-16 |
2012-08-10 |
Bristol-Myers Squibb Company |
Proceso para separar una mezcla de enantiómeros de éster alquílico usando una enzima
|
EP1628685B1
(fr)
|
2003-04-25 |
2010-12-08 |
Gilead Sciences, Inc. |
Analogues phosphonates antiviraux
|
US7300924B2
(en)
|
2003-04-25 |
2007-11-27 |
Gilead Sciences, Inc. |
Anti-infective phosphonate analogs
|
EP1622870A2
(fr)
|
2003-05-05 |
2006-02-08 |
Prosidion Ltd. |
Inhibiteurs de la dp iv a base de glutaminyle
|
CA2734052A1
(fr)
*
|
2003-05-30 |
2005-01-13 |
Pharmasset, Inc. |
Analogues de nucleosides fluores modifies
|
US7273851B2
(en)
|
2003-06-05 |
2007-09-25 |
Enanta Pharmaceuticals, Inc. |
Tri-peptide hepatitis C serine protease inhibitors
|
US7125845B2
(en)
|
2003-07-03 |
2006-10-24 |
Enanta Pharmaceuticals, Inc. |
Aza-peptide macrocyclic hepatitis C serine protease inhibitors
|
JP4685775B2
(ja)
|
2003-09-18 |
2011-05-18 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
セリンプロテアーゼ、とりわけhcvns3−ns4aプロテアーゼの阻害剤
|
KR20120010278A
(ko)
|
2003-10-10 |
2012-02-02 |
버텍스 파마슈티칼스 인코포레이티드 |
세린 프로테아제, 특히 hcv ns3-ns4a 프로테아제의 억제제
|
JP4584260B2
(ja)
*
|
2003-10-14 |
2010-11-17 |
インターミューン・インコーポレーテッド |
Hcv複製阻害剤としての大環状カルボン酸およびアシルスルホンアミド
|
US7491794B2
(en)
|
2003-10-14 |
2009-02-17 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
AU2004285019B9
(en)
|
2003-10-27 |
2011-11-24 |
Vertex Pharmaceuticals Incorporated |
HCV NS3-NS4A protease resistance mutants
|
US7132504B2
(en)
|
2003-11-12 |
2006-11-07 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
JP2007516239A
(ja)
|
2003-11-20 |
2007-06-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
特に複分解反応生成物からの、遷移金属の除去方法
|
US7309708B2
(en)
|
2003-11-20 |
2007-12-18 |
Birstol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP1742913A1
(fr)
|
2003-12-11 |
2007-01-17 |
Schering Corporation |
Inhibiteurs de la protease serine ns3/ns4a du virus de l'hepatite c (hcv)
|
CA2549851C
(fr)
|
2004-01-21 |
2012-09-11 |
Boehringer Ingelheim International Gmbh |
Peptides macrocycliques actifs contre le virus de l'hepatite c
|
DE602005017582D1
(en)
|
2004-01-30 |
2009-12-24 |
Medivir Ab |
Hcv ns-3 serine protease inhibitoren
|
CA2554999A1
(fr)
|
2004-02-04 |
2005-08-25 |
Vertex Pharmaceuticals Incorporated |
Inhibiteurs de proteases serines, en particulier de la protease hcv ns3-ns4a
|
KR20060124725A
(ko)
|
2004-02-27 |
2006-12-05 |
쉐링 코포레이션 |
C형 간염 바이러스 ns3 프로테아제의 억제제
|
ATE438622T1
(de)
|
2004-02-27 |
2009-08-15 |
Schering Corp |
3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
|
EP1939213B1
(fr)
|
2004-02-27 |
2010-08-25 |
Schering Corporation |
Nouveaux composés en tant qu'inhibiteurs de la sérine protéase NS3 du virus de l'hépatite C
|
US7816326B2
(en)
|
2004-02-27 |
2010-10-19 |
Schering Corporation |
Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
|
EP1730142B1
(fr)
|
2004-02-27 |
2011-06-29 |
Schering Corporation |
Nouveaux cetoamides a p4 cycliques en tant qu'inhibiteurs de la ns3 serine protease du virus de l'hepatite c
|
JP4654239B2
(ja)
|
2004-03-15 |
2011-03-16 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
C型肝炎ウィルス感染症の治療に適した大環状ジペプチドの調製方法
|
EP1773868B1
(fr)
|
2004-05-20 |
2009-07-15 |
Schering Corporation |
Prolines substituées en tant qu`inhibiteurs de la sérine protéase du virus ns3 de l`hépatite c
|
JP5156374B2
(ja)
|
2004-05-25 |
2013-03-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
非環式hcvプロテアーゼインヒビターの調製方法
|
US7939538B2
(en)
|
2004-06-28 |
2011-05-10 |
Amgen Inc. |
Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
|
DE102004033312A1
(de)
|
2004-07-08 |
2006-01-26 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren
|
BRPI0513370A
(pt)
*
|
2004-07-14 |
2008-05-06 |
Novartis Ag |
uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
|
PL1778702T3
(pl)
|
2004-07-16 |
2011-12-30 |
Gilead Sciences Inc |
Związki przeciwwirusowe
|
ATE512971T1
(de)
|
2004-07-20 |
2011-07-15 |
Boehringer Ingelheim Int |
Peptidanaloga als hepatitis c-hemmer
|
ATE513844T1
(de)
|
2004-08-27 |
2011-07-15 |
Schering Corp |
Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
|
WO2006033851A1
(fr)
|
2004-09-17 |
2006-03-30 |
Boehringer Ingelheim International, Gmbh |
Réaction de métathèse cyclisante en milieu fluide supercritique
|
US7323447B2
(en)
|
2005-02-08 |
2008-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7524831B2
(en)
|
2005-03-02 |
2009-04-28 |
Schering Corporation |
Treatments for Flaviviridae virus infection
|
US7674612B2
(en)
|
2005-03-04 |
2010-03-09 |
The Rockefeller University |
Infectious, chimeric hepatitis C virus, methods of producing the same and methods of use thereof
|
DK1863833T3
(da)
|
2005-03-08 |
2013-12-02 |
Boehringer Ingelheim Int |
Fremgangsmåde til fremstilling af makrocykliske forbindelser
|
AU2006242475B2
(en)
|
2005-05-02 |
2011-07-07 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
CN101184771A
(zh)
|
2005-05-26 |
2008-05-21 |
先灵公司 |
干扰素-IgG融合体
|
US20060275366A1
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Controlled-release formulation
|
WO2006130627A2
(fr)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methodes de traitement de l'hepatite c
|
US7608592B2
(en)
|
2005-06-30 |
2009-10-27 |
Virobay, Inc. |
HCV inhibitors
|
US7601686B2
(en)
|
2005-07-11 |
2009-10-13 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
TWI389908B
(zh)
|
2005-07-14 |
2013-03-21 |
Gilead Sciences Inc |
抗病毒化合物類
|
US7470664B2
(en)
|
2005-07-20 |
2008-12-30 |
Merck & Co., Inc. |
HCV NS3 protease inhibitors
|
JP5249028B2
(ja)
*
|
2005-07-25 |
2013-07-31 |
インターミューン・インコーポレーテッド |
C型肝炎ウイルス複製の新規大環状阻害剤
|
PT1912997E
(pt)
|
2005-07-29 |
2011-12-19 |
Tibotec Pharm Ltd |
Inibidores macrocíclicos do vírus da hepatite c
|
DK1999129T3
(da)
|
2005-10-11 |
2011-02-07 |
Intermune Inc |
Forbindelser og fremgangsmåder til inhibering af replikationen af hepatitis C-virus
|
US7772183B2
(en)
|
2005-10-12 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7741281B2
(en)
|
2005-11-03 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7705138B2
(en)
|
2005-11-11 |
2010-04-27 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
EP1951717A1
(fr)
|
2005-11-16 |
2008-08-06 |
F.Hoffmann-La Roche Ag |
Derives innovants de la pyrrolidine en tant qu'inhibiteurs du facteur de coagulation xa
|
NZ568909A
(en)
*
|
2005-12-09 |
2011-10-28 |
Hoffmann La Roche |
Antiviral 4-fluoro-4-methyl nucleoside prodrugs
|
US7728148B2
(en)
|
2006-06-06 |
2010-06-01 |
Enanta Pharmaceuticals, Inc. |
Acyclic oximyl hepatitis C protease inhibitors
|
US9526769B2
(en)
|
2006-06-06 |
2016-12-27 |
Enanta Pharmaceuticals, Inc. |
Macrocylic oximyl hepatitis C protease inhibitors
|
EP2029741A4
(fr)
|
2006-06-08 |
2011-03-16 |
Merck Sharp & Dohme |
Procédé rapide pour déterminer la sensibilité aux inhibiteurs de séquences de protéase ns3/4a clonées à partir d'échantillons cliniques
|
PE20080992A1
(es)
|
2006-06-26 |
2008-08-06 |
Enanta Pharm Inc |
Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c
|
KR20090024834A
(ko)
|
2006-07-05 |
2009-03-09 |
인터뮨, 인크. |
C형 간염 바이러스 복제의 신규 억제제
|
TWI399377B
(zh)
*
|
2006-07-07 |
2013-06-21 |
Gilead Sciences Inc |
類鐸受體7之調節劑
|
EP2049474B1
(fr)
|
2006-07-11 |
2015-11-04 |
Bristol-Myers Squibb Company |
Inhibiteurs du virus de l'hépatite c
|
WO2008008502A1
(fr)
|
2006-07-13 |
2008-01-17 |
Achillion Pharmaceuticals, Inc. |
4-amino-4-oxobutanoyl peptides en tant qu'inhibiteurs de la réplication virale
|
US7718612B2
(en)
|
2007-08-02 |
2010-05-18 |
Enanta Pharmaceuticals, Inc. |
Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
|
US20090035267A1
(en)
|
2007-07-31 |
2009-02-05 |
Moore Joel D |
Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
|
WO2008019289A2
(fr)
|
2006-08-04 |
2008-02-14 |
Enanta Pharmaceuticals, Inc. |
Inhibiteurs de sérine protéases de l'hépatite c macrocycliques de type tétrazolyle
|
US7635683B2
(en)
|
2006-08-04 |
2009-12-22 |
Enanta Pharmaceuticals, Inc. |
Quinoxalinyl tripeptide hepatitis C virus inhibitors
|
US7687459B2
(en)
|
2006-08-11 |
2010-03-30 |
Enanta Pharmaceuticals, Inc. |
Arylalkoxyl hepatitis C virus protease inhibitors
|
US20080038225A1
(en)
|
2006-08-11 |
2008-02-14 |
Ying Sun |
Triazolyl acyclic hepatitis c serine protease inhibitors
|
US20090098085A1
(en)
|
2006-08-11 |
2009-04-16 |
Ying Sun |
Tetrazolyl acyclic hepatitis c serine protease inhibitors
|
US7662779B2
(en)
|
2006-08-11 |
2010-02-16 |
Enanta Pharmaceuticals, Inc. |
Triazolyl macrocyclic hepatitis C serine protease inhibitors
|
US20090035268A1
(en)
|
2007-08-01 |
2009-02-05 |
Ying Sun |
Tetrazolyl acyclic hepatitis c serine protease inhibitors
|
US7605126B2
(en)
|
2006-08-11 |
2009-10-20 |
Enanta Pharmaceuticals, Inc. |
Acylaminoheteroaryl hepatitis C virus protease inhibitors
|
US20120220520A1
(en)
*
|
2006-10-17 |
2012-08-30 |
Van T Klooster Gerben Albert Eleutherius |
Bioavailable combinations for hcv treatment
|
US20080107625A1
(en)
|
2006-11-01 |
2008-05-08 |
Bristol-Myers Squibb Company |
Inhibitors of Hepatitis C Virus
|
US8343477B2
(en)
|
2006-11-01 |
2013-01-01 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
US20080107623A1
(en)
|
2006-11-01 |
2008-05-08 |
Bristol-Myers Squibb Company |
Inhibitors of Hepatitis C Virus
|
US7772180B2
(en)
|
2006-11-09 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2661338C
(fr)
|
2006-11-17 |
2015-05-12 |
Tibotec Pharmaceuticals Ltd. |
Inhibiteurs macrocycliques du virus de l'hepatite c
|
US20080261913A1
(en)
|
2006-12-28 |
2008-10-23 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of liver disorders
|
US20100087382A1
(en)
|
2007-02-16 |
2010-04-08 |
Boehringer Ingelheim International Gmbh |
Inhibitors of Hepatitis C NS3 Protease
|
CA2681624A1
(fr)
|
2007-03-23 |
2009-01-15 |
Schering Corporation |
Inhibiteurs de cetoamides de p1 non epimerisables de protease de ns3 du virus de l'hepatite c (vhc)
|
CN101663294A
(zh)
|
2007-04-24 |
2010-03-03 |
弗·哈夫曼-拉罗切有限公司 |
Hcv蛋白酶抑制剂中间体的制备方法
|
US20080317712A1
(en)
|
2007-04-26 |
2008-12-25 |
Deqiang Niu |
Arylpiperidinyl and arylpyrrolidinyl tripeptide hepatitis c serine protease inhibitors
|
US7906513B2
(en)
|
2007-04-26 |
2011-03-15 |
Enanta Pharmaceuticals, Inc. |
Hydrazide-containing hepatitis C serine protease inhibitors
|
US7910587B2
(en)
|
2007-04-26 |
2011-03-22 |
Enanta Pharmaceuticals, Inc. |
Quinoxalinyl dipeptide hepatitis C virus inhibitors
|
US20080274082A1
(en)
|
2007-04-26 |
2008-11-06 |
Yonghua Gai |
Oximyl hydroxyamic analogs as hepatitis c virus protease inhibitor
|
US8377872B2
(en)
|
2007-04-26 |
2013-02-19 |
Enanta Pharmaceuticals, Inc. |
Cyclic P3 tripeptide hepatitis C serine protease inhibitors
|
US20090123423A1
(en)
|
2007-04-26 |
2009-05-14 |
Yonghua Gai |
Hydroxyamic analogs as hepatitis c virus serine protease inhibitor
|
US20080274080A1
(en)
|
2007-04-26 |
2008-11-06 |
Yat Sun Or |
Aza-peptide macrocyclic hepatitis c serine protease inhibitors
|
US20080279821A1
(en)
|
2007-04-26 |
2008-11-13 |
Deqiang Niu |
Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors
|
US20080267917A1
(en)
|
2007-04-26 |
2008-10-30 |
Deqiang Niu |
N-functionalized amides as hepatitis c serine protease inhibitors
|
CL2008001274A1
(es)
|
2007-05-03 |
2008-11-03 |
Intermune Inc Y Array Biopharma Inc |
Compuestos macrolidos derivados de 5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropan[e]pirrolo[1,2-a][1,4]diazaciclopentadecinilo, inhibidores de la actividad de la proteasa ns3-ns4; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios y procedimiento de preparacion; y uso en el tratamiento de.....
|
BRPI0811447A2
(pt)
|
2007-05-10 |
2014-10-29 |
Intermune Inc |
Compostos, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática e de intensificação da função hepática num indivíduo tendo infecção de vírus da hepatite c.
|
JP2010528013A
(ja)
*
|
2007-05-21 |
2010-08-19 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Vx−950を含む用量形態およびそれらの投与レジメン
|
US20090005387A1
(en)
|
2007-06-26 |
2009-01-01 |
Deqiang Niu |
Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
|
WO2009014730A1
(fr)
|
2007-07-26 |
2009-01-29 |
Idenix Pharmaceuticals, Inc. |
Inhibiteurs macrocycliques de la sérine protéase
|
US20090053175A1
(en)
|
2007-08-24 |
2009-02-26 |
Yat Sun Or |
Substitute pyrrolidine derivatives
|
US20090060874A1
(en)
|
2007-09-05 |
2009-03-05 |
Yao-Ling Qiu |
Bicyclic pyrrolidine derivatives
|
CA2700383A1
(fr)
|
2007-09-24 |
2009-04-02 |
Achillion Pharmaceuticals, Inc. |
Peptides contenant de l'uree en tant qu'inhibiteurs de la replication virale
|
US20090082366A1
(en)
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched telaprevir
|
US20090111757A1
(en)
|
2007-10-25 |
2009-04-30 |
Taigen Biotechnology Co., Ltd. |
Hcv protease inhibitors
|
US8383583B2
(en)
|
2007-10-26 |
2013-02-26 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
|
US8426360B2
(en)
|
2007-11-13 |
2013-04-23 |
Enanta Pharmaceuticals, Inc. |
Carbocyclic oxime hepatitis C virus serine protease inhibitors
|
WO2009076166A2
(fr)
|
2007-12-05 |
2009-06-18 |
Enanta Pharmaceuticals, Inc. |
Inhibiteurs oximyles de la sérine protéase de vhc
|
WO2009085978A1
(fr)
|
2007-12-20 |
2009-07-09 |
Enanta Pharceuticals, Inc. |
Inhibiteurs de protéase de sérine de virus de l'hépatite c d'oxime carbocyclique couronnés
|
KR101629523B1
(ko)
|
2007-12-21 |
2016-06-10 |
에프. 호프만-라 로슈 아게 |
대환 화합물의 제조방법
|
KR20100118991A
(ko)
|
2008-02-04 |
2010-11-08 |
아이데닉스 파마슈티칼스, 인코포레이티드 |
매크로시클릭 세린 프로테아제 억제제
|
US8211897B2
(en)
|
2008-02-07 |
2012-07-03 |
Virobay, Inc. |
Inhibitors of cathepsin B
|
SI2276725T1
(sl)
|
2008-04-11 |
2012-09-28 |
Hoffmann La Roche |
Novi rutenijevi kompleksi kot katalizatorji za metatezne reakcije
|
US8048862B2
(en)
|
2008-04-15 |
2011-11-01 |
Intermune, Inc. |
Macrocyclic inhibitors of hepatitis C virus replication
|
WO2009134987A1
(fr)
|
2008-04-30 |
2009-11-05 |
Enanta Pharmaceuticals, Inc. |
Composés macrocycliques contenant du difluorométhyle comme inhibiteurs du virus de l’hépatite c
|
US20090285773A1
(en)
|
2008-05-15 |
2009-11-19 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US20090285774A1
(en)
|
2008-05-15 |
2009-11-19 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
CN101580535B
(zh)
|
2008-05-16 |
2012-10-03 |
太景生物科技股份有限公司 |
丙型肝炎病毒蛋白酶抑制剂
|
US8044023B2
(en)
|
2008-05-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
KR20110065440A
(ko)
|
2008-07-02 |
2011-06-15 |
아이데닉스 파마슈티칼스, 인코포레이티드 |
바이러스 감염의 치료를 위한 화합물 및 제약 조성물
|
US7906655B2
(en)
|
2008-08-07 |
2011-03-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
KR101647520B1
(ko)
|
2008-08-07 |
2016-08-10 |
에프. 호프만-라 로슈 아게 |
거대환식 화합물의 제조 방법
|
EP2337583A1
(fr)
|
2008-09-17 |
2011-06-29 |
Boehringer Ingelheim International GmbH |
Association de l'inhibiteur protéase hcv ns3 avec de l'interféron et de la ribavirine
|
US8603737B2
(en)
|
2008-09-19 |
2013-12-10 |
Celgene Avilomics Research, Inc. |
Methods for identifying HCV protease inhibitors
|
US8044087B2
(en)
|
2008-09-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US20100080770A1
(en)
|
2008-09-29 |
2010-04-01 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US8563505B2
(en)
|
2008-09-29 |
2013-10-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2010045266A1
(fr)
|
2008-10-15 |
2010-04-22 |
Intermune, Inc. |
Peptides antiviraux therapeutiques
|
JP5689810B2
(ja)
|
2008-11-20 |
2015-03-25 |
アキリオン ファーマシューティカルズ,インコーポレーテッド |
C型肝炎ウイルス用の環状カルボキサミド化合物およびその類似体
|
NZ592705A
(en)
|
2008-12-10 |
2013-02-22 |
Achillion Pharmaceuticals Inc |
4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
|
US8283310B2
(en)
|
2008-12-15 |
2012-10-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2747636A1
(fr)
|
2008-12-19 |
2010-07-15 |
Gilead Sciences, Inc. |
Inhibiteurs de la protease ns3 du vhc
|
CA2746834A1
(fr)
|
2008-12-22 |
2010-07-01 |
Gilead Sciences, Inc. |
Composes antiviraux
|
US20100196321A1
(en)
|
2009-01-30 |
2010-08-05 |
Glaxosmithkline Llc |
Compounds
|
TWI438200B
(zh)
|
2009-02-17 |
2014-05-21 |
必治妥美雅史谷比公司 |
C型肝炎病毒抑制劑
|
AR075584A1
(es)
|
2009-02-27 |
2011-04-20 |
Intermune Inc |
COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
|
US8377962B2
(en)
|
2009-04-08 |
2013-02-19 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
HUE040182T2
(hu)
|
2009-04-25 |
2019-02-28 |
Hoffmann La Roche |
Farmakokinetikai módszerek javítására szolgáló módszerek
|
AR077139A1
(es)
|
2009-06-23 |
2011-08-03 |
Gilead Sciences Inc |
Composiciones farmaceuticas utiles para tratar el vch
|
UY32721A
(es)
|
2009-06-23 |
2011-01-31 |
Gilead Sciences Ltd |
Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
|
WO2010151472A1
(fr)
|
2009-06-23 |
2010-12-29 |
Gilead Sciences, Inc. |
Combinaison d'un inhibiteur de polymérase ns5b et d'un inhibiteur de protéase ns3 du virus de l'hépatite c (vhc) pour le traitement du vhc
|
US8232246B2
(en)
|
2009-06-30 |
2012-07-31 |
Abbott Laboratories |
Anti-viral compounds
|
CN102712644A
(zh)
|
2009-09-28 |
2012-10-03 |
豪夫迈·罗氏有限公司 |
丙肝病毒复制的新型大环抑制剂
|